ELOXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Eloxx Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$12.50−0.53 (-4.07%)
Close on Oct 19, 2026
- Market cap
- $84.86M
- P/E (TTM)
- –
- Dividend yield
- –
Eloxx Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Eloxx Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $50.46M | $197.05M |
| Enterprise Value | -$11.50M | $106.56M |
| PB Ratio | 1.09 | 2.14 |
| P/TBV Ratio | 1.09 | 2.46 |
Income (trailing twelve months)
| Measure | Eloxx Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $0 | $57.94M |
| Operating Income | -$6.44M | -$21.44M |
| Pretax Income | -$6.00M | -$14.45M |
| Net Income | -$6.00M | -$22.46M |
| EBITDA | -$6.44M | -$16.91M |
| EPS (Diluted) | -$0.49 | -$0.83 |
Returns
| Measure | Eloxx Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -64.7% | -53.1% |
| Return on Assets (ROA) | -9.46% | -41.0% |
| Return on Capital Employed (ROCE) | -13.9% | -37.8% |
Growth
| Measure | Eloxx Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -100.0% | 6.01% |
Balance sheet
| Measure | Eloxx Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $61.96M | $62.42M |
| Total Debt | $0 | $120.13M |
| Net Cash (Debt) | $61.96M | $15.68M |
| Net Cash Per Share | $15.35 | $0.65 |
| Equity (Book Value) | $46.42M | $48.79M |
| Book Value Per Share | $11.50 | $1.36 |
| Tangible Book Value | $46.42M | $23.06M |
| Working Capital | $46.42M | $75.77M |
Financial position
| Measure | Eloxx Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 3.74 | 3.30 |
| Quick Ratio | 3.65 | 2.39 |
| Debt / Equity | 0.00 | 0.51 |
Cash flow (trailing twelve months)
| Measure | Eloxx Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$6.33M | -$12.35M |
Efficiency
| Measure | Eloxx Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.00 | 0.38 |
| Revenue Per Employee | $0 | $398.96K |
| Profits Per Employee | -$856.43K | -$732.08K |
| Employee Count | 7 | 73 |
Dividends and yields
| Measure | Eloxx Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -11.9% | -21.2% |
| Buyback Yield | 0.00% | -0.58% |
| Shareholder Yield | 0.00% | 0.00% |
Shares
| Measure | Eloxx Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 4,036,460 | 59,128,900 |
| Shares Change (YoY) | 228.5% | 11.1% |
| Shares Change (QoQ) | -20.4% | 0.54% |
| Float | 2,317,760 | 48,744,500 |
| Shares Held by Insiders | 42.6% | 11.8% |
| Shares Held by Institutions | 71.8% | 59.4% |
Taxes
| Measure | Eloxx Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | $0 | $91.50K |
Scores
| Measure | Eloxx Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | -4.49 | 0.10 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Eloxx Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.